Kymera Therapeutics KYMR
NASDAQ KYMR
$117.45 +0.17 (+0.14%)
As of: Sep 4, 2026 · 3:59 PM EDT

Kymera Therapeutics (KYMR) Amortization of Deferred Charges (2020 - 2026)

Analysis

Kymera Therapeutics (KYMR) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Kymera Therapeutics 11.52 Bn 10.83 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -2.33 Mn
Mar 31, 2026 -2.73 Mn
Dec 31, 2025 -2.05 Mn
Sep 30, 2025 -2.19 Mn
Jun 30, 2025 -2.12 Mn
Mar 31, 2025 -2.53 Mn
Dec 31, 2024 -3.27 Mn
Sep 30, 2024 -3.62 Mn
Jun 30, 2024 -4.02 Mn
Mar 31, 2024 -3.07 Mn
Dec 31, 2023 -1.27 Mn
Sep 30, 2023 -1.22 Mn
Jun 30, 2023 -1.42 Mn
Mar 31, 2023 -1.33 Mn
Dec 31, 2022 -905,000.00
Sep 30, 2022 -58,000.00
Jun 30, 2022 677,000.00
Mar 31, 2022 1.18 Mn
Dec 31, 2021 1.64 Mn
Sep 30, 2021 1.66 Mn